ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL04. National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L04A Immunosuppressants
L04AA Selective immunosuppressants
L04AA03 Antilymphocyte immunoglobulin (horse) L04AA04 Antithymocyte immunoglobulin (rabbit) L04AA06 Mycophenolic acid L04AA15 Alefacept L04AA19 Gusperimus L04AA22 Abetimus L04AA24 Abatacept L04AA28 Belatacept L04AA32 Apremilast L04AA40 Cladribine L04AA41 Imlifidase L04AA48 Belumosudil L04AA58 Efgartigimod alfa L04AA60 RemibrutinibL04AB Tumor necrosis factor alpha (TNF-α) inhibitors
L04AB01 Etanercept L04AB02 Infliximab L04AB03 Afelimomab L04AB04 Adalimumab L04AB05 Certolizumab pegol L04AB06 Golimumab L04AB07 OpinerceptL04AC Interleukin inhibitors
L04AC01 Daclizumab L04AC02 Basiliximab L04AC03 Anakinra L04AC04 Rilonacept L04AC05 Ustekinumab L04AC07 Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab L04AC11 Siltuximab L04AC12 Brodalumab L04AC13 Ixekizumab L04AC14 Sarilumab L04AC15 Sirukumab L04AC16 Guselkumab L04AC17 Tildrakizumab L04AC18 Risankizumab L04AC19 Satralizumab L04AC20 Netakimab L04AC21 Bimekizumab L04AC22 Spesolimab L04AC23 Olokizumab L04AC26 GoflikiceptL04AD Calcineurin inhibitors
L04AD01 Ciclosporin L04AD02 Tacrolimus L04AD03 VoclosporinL04AE Sphingosine 1-phosphate (S1P) receptor modulators
L04AE01 Fingolimod L04AE02 Ozanimod L04AE03 Siponimod L04AE04 Ponesimod L04AE05 EtrasimodL04AF Janus-associated kinase (JAK) inhibitors
L04AF01 Tofacitinib L04AF02 Baricitinib L04AF03 Upadacitinib L04AF04 Filgotinib L04AF05 Itacitinib L04AF06 Peficitinib L04AF07 Deucravacitinib L04AF08 RitlecitinibL04AG Monoclonal antibodies
L04AG01 Muromonab-CD3 L04AG02 Efalizumab L04AG03 Natalizumab L04AG04 Belimumab L04AG05 Vedolizumab L04AG06 Alemtuzumab L04AG07 Begelomab L04AG08 Ocrelizumab L04AG09 Emapalumab L04AG10 Inebilizumab L04AG11 Anifrolumab L04AG12 Ofatumumab L04AG13 Teprotumumab L04AG14 Ublituximab L04AG15 Divozilimab L04AG16 Rozanolixizumab L04AG17 SeniprutugL04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
L04AH01 Sirolimus L04AH02 EverolimusL04AJ Complement inhibitors
L04AJ01 Eculizumab L04AJ02 Ravulizumab L04AJ03 Pegcetacoplan L04AJ04 Sutimlimab L04AJ05 Avacopan L04AJ06 Zilucoplan L04AJ07 Crovalimab L04AJ08 Iptacopan L04AJ09 Danicopan L04AJ10 Vilobelimab L04AJ11 PozelimabL04AK Dihydroorotate dehydrogenase (DHODH) inhibitors
L04AK01 Leflunomide L04AK02 TeriflunomideL04AX Other immunosuppressants
L04AX01 Azathioprine L04AX02 Thalidomide L04AX03 Methotrexate L04AX04 Lenalidomide L04AX05 Pirfenidone L04AX06 Pomalidomide L04AX07 Dimethyl fumarate L04AX08 Darvadstrocel L04AX09 Diroximel fumarate L04AX10 Tegomil fumarateReferences
"ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020. https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/ATC/index.html ↩
"Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022. https://www.who.int/tools/atc-ddd-toolkit/atc-classification ↩
"Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022. https://www.whocc.no/atc/structure_and_principles/ ↩
"ATC/DDD Index 2022: code L04". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/?code=L04 ↩
"ATCvet Index 2022: code QL04". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcvet/atcvet_index/?code=L04 ↩